Table 2 Antifungal use among hospitals based on patient group
Antifungal agent | Neonates: n = 54; 100,155 admissions | Pediatrics: n = 44; 159,936 admissions | Adults: n = 60; 1,841,667 admissions | ANOVA (F-statistic) |
|---|---|---|---|---|
Total antifungals* | 14.4 (10.7 to 18.2) | 75.8 (56.6 to 95.1) | 73.2 (62.7 to 84.4) | p < 0.001 (34.8) |
Azoles* | 12.3 (8.6 to 15.6) | 54.6 (40.8 to 68.4) | 55.1 (47.2 to 63.4) | p < 0.001 (32.7) |
Fluconazole | 12.2 (8.8 to 15.6) | 40.6 (31.7 to 49.4) | 37.9 (33.3 to 42.4) | |
Voriconazole | 0.03 (− 0.03 to 0.09) | 12.5 (6 to 19) | 10 (7.8 to 12.3) | |
Posaconazole | 0 | 0.91 (− 0.02 to 1.8) | 5.8 (3.4 to 8.3) | |
Itraconazole | 0 | 0.61 (0.12 to 1.1) | 1.3 (0.58 to 2.1) | |
Amphotericin B* | 1.4 (0.71 to 2.1) | 3.8 (1.9 to 5.7) | 3.9 (3.0 to 4.8) | p = 0.0021 (6.1) |
Conventional | 0.66 (0.23 to 1.1) | 0.78 (− 0.07 to 1.6) | 1.3 (0.76 to 1.9) | |
Liposomal | 0.25 (0.03 to 0.47) | 2.3 (0.72 to 3.9) | 2.1 (1.5 to 2.6) | |
Lipid complex | 0.5 (−0.018 to 1.02) | 0.72 (− 0.002 to 1.43) | 0.5 (0.24 to 0.78) | |
Echinocandins* | 0.76 (0.32 to 1.2) | 17.4 (11.4 to 23.5) | 14.3 (11.8 to 16.8) | p < 0.001 (28) |
Caspofungin | 0.17 (−0.005 to 0.34) | 4.9 (0.5 to 9.3) | 2.9 (1.2 to 4.6) | |
Micafungin | 0.59 (0.21 to 0.98) | 12.5 (7.3 to 17.8) | 10.4 (7.9 to 12.9) | |
Anidulafungin | 0 | 0 | 1 (0.4 to 1.7) |